International
U.S. Drug Pricing Pressure: Pharma’s Reliance and Negotiation Strategies Amid Changing Landscape
The U.S. is the largest market for pharmaceutical firms, with many companies heavily reliant on American sales due to high drug prices. Amid calls for lower costs, companies are negotiating with the Trump administration, although analysts question the potential impact on their finances.
The U.S. stands as the largest market for pharmaceutical and biotech companies, with significant reliance on American sales due to higher drug prices that can be nearly three times as high as in other countries. Among the ten largest biopharmaceutical firms in the Stoxx 600 health index, five generate a majority of their sales from the U.S., with Argenx being the most heavily reliant at 85%. AstraZeneca, a leading company in the FTSE 100, currently derives 42% of its sales from the U.S. and aims to increase this share as part of a strategy to achieve $80 billion in revenue by 2030. The ongoing conversation around drug pricing has seen President Trump advocate for reduced costs through initiatives like the Most Favored Nations pricing model, which aligns U.S. prices with the lowest prices in other wealthy nations. This push has prompted pharmaceutical firms to enter negotiations with the administration to lower prescription prices, while also facing increased pressure to onshore production. Companies like AstraZeneca, Novo Nordisk, and Roche have begun to respond to these pressures, with potential deals in the pipeline aimed at meeting the administration’s goals. Despite efforts to negotiate lower prices, analysts express skepticism regarding the significant impact these deals will have on the companies’ financial health.
SOURCE: CNBC
